TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27085886

Group type: EXPERIMENTAL
Intervention: PEP 1 cmH2O
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PEP 10 cmH2O
Number of subjects: 72

Group type: COMPARATOR
Intervention: Baseline (no PEP)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Comparison between PEP 1 cmH2O and PEP 10 cmH2O
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pulmonary function and physiological variables
Number of subjects: 72
Study: 24684600

Group type: EXPERIMENTAL
Intervention: Emergency nurse practitioner service
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard emergency department care
Number of subjects: 260
Study: 21958930

Group type: EXPERIMENTAL
Intervention: Quality-controlled CPR performed by a dedicated medical emergency team using a Philips HeartStart MRx defibrillator.
Number of subjects: 9
Study: 20435962

Group type: EXPERIMENTAL
Intervention: Specialised care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 17277734

Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz, 30 minutes, 110% of motor threshold over the right dorso‐lateral prefrontal cortex)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study: 15367922

Group type: EXPERIMENTAL
Intervention: 15 g alcohol/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 30 g alcohol/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: No-alcohol placebo beverage
Number of subjects: 53
Study: 12218503

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with bolus intravenous doses of 1 mg morphine for 3 days
Number of subjects: 625
Study: 9800817

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene patches
Number of subjects: 52

Group type: COMPARATOR
Intervention: Polyglycolic acid patches
Number of subjects: 52
Study: 7666085

Group type: EXPERIMENTAL
Intervention: Escalated MVAC with rhGM‐CSF
Number of subjects: 48

Group type: COMPARATOR
Intervention: Escalated MVAC alone
Number of subjects: 48
Study: 2777422

Group type: EXPERIMENTAL
Intervention: 60 mg of sustained-release urapidil (Ebrantil 60)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 50 mg urapidil (fast-release tablet)
Number of subjects: 12
Study: 30998290

Group type: EXPERIMENTAL
Intervention: ExerciseUP (home-based integrated physical exercise and bladder training with urge suppression and fall prevention program)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ExerciseUP
Number of subjects: 38

Group type: COMPARATOR
Intervention: ExerciseUP and Usual care
Number of subjects: 38
Study: 26975647

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 23934387

Group type: EXPERIMENTAL
Intervention: US-guided IA injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palpation-guided IA injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both US-guided and palpation-guided IA injections
Number of subjects: 60
Study: 22794665

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) for 8 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: No active treatment (Control)
Number of subjects: 29
Study: 20233509

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 18525393

Group type: EXPERIMENTAL
Intervention: High altitude exercise
Number of subjects: 8
Study: 15673896

Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine (30 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Procaine (80 mg)
Number of subjects: 8
Study: 14738262

Group type: EXPERIMENTAL
Intervention: Midazolam 0.02 mg x kg(-1) followed by thiopentone 3 mg x kg(-1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thiopentone and midazolam co-induction
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 9737654

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium-channel blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic antiarrhythmic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition of proarrhythmia and withdrawal of offending agents
Number of subjects: 0
Study: 1761344

Group type: EXPERIMENTAL
Intervention: Solid state ambulatory monitoring devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequency modulated recording device
Number of subjects: 0
Study: 6804113

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol, 160 mg once daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard propranolol, 40 mg four times daily for 4 weeks
Number of subjects: 20
Study: 31222951

Group type: EXPERIMENTAL
Intervention: Roxadustat 50 or 70 mg three times weekly (ESA-Naïve group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Roxadustat 70 or 100 mg three times weekly (ESA-Converted group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Roxadustat (both groups)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Roxadustat (ESA-Naïve group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Roxadustat (ESA-Converted group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 56
Study: 30299415

Group type: EXPERIMENTAL
Intervention: Deep drain
Number of subjects: 100

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 100
Study: 28744099

Group type: EXPERIMENTAL
Intervention: Verinurad (40 mg, single dose)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Verinurad (10 mg, multiple dose)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Verinurad (≥2 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Verinurad (single and multiple doses)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Verinurad (fasted and fed states)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Verinurad (multiple daily doses)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 27046160

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 or 60 mg twice daily)
Number of subjects: 6806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6806
Study: 24442532

Group type: EXPERIMENTAL
Intervention: Cup feeding
Number of subjects: 522

Group type: COMPARATOR
Intervention: Bottle feeding
Number of subjects: 522

Group type: COMPARATOR
Intervention: Cup feeding and Bottle feeding
Number of subjects: 522
Study: 22585772

Group type: EXPERIMENTAL
Intervention: Maternal antiretrovirals (ARVs) during pregnancy, labor, and postpartum
Number of subjects: 236
Study: 19938709

Group type: EXPERIMENTAL
Intervention: Synthetic colloid solutions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17674759

Group type: EXPERIMENTAL
Intervention: Group A: Postoperative management at one week after operation, then weekly for the first and second month, bi-weekly for the third and fourth month, and monthly after the fifth month.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group B: Postoperative management at two weeks after operation, then bi-weekly for the first and second month, monthly from third to fifth month, and bi-monthly after sixth month.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group A: Rate of epithelialization measured at third month.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group B: Rate of epithelialization measured at third month.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group A: Efficiency rate measured at twelfth month.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group B: Efficiency rate measured at twelfth month.
Number of subjects: 80
Study: 15206017

Group type: EXPERIMENTAL
Intervention: 150 mg procaine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 0
Study: 11199949

Group type: EXPERIMENTAL
Intervention: Opipramol (200 mg/day)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Alprazolam (2 mg/day)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 9472839

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/24 hr for 8 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7594335

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: famotidine 20 mg twice daily
Number of subjects: 24
Study: 2174652

Group type: EXPERIMENTAL
Intervention: 40 ml 0.75% prilocaine hydrochloride with 5 ml 8.4% sodium bicarbonate
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5 ml 0.9% saline
Number of subjects: 80
Study: 6986111

Group type: EXPERIMENTAL
Intervention: Predictive instrument used in emergency room during experimental months (401 patients)
Number of subjects: 856

Group type: COMPARATOR
Intervention: Control months (455 patients)
Number of subjects: 856
Study: 31935834

Group type: EXPERIMENTAL
Intervention: Self-initiated downward referral
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Doctor's advice
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Factors influencing willingness for downward referral
Number of subjects: 1198
Study: 31185917

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia and analgesia (EGA group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia (GA group, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EGA group
Number of subjects: 40

Group type: COMPARATOR
Intervention: GA group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 27657979

Group type: EXPERIMENTAL
Intervention: Vets Prevail program
Number of subjects: 303

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 303
Study: 25209545

Group type: EXPERIMENTAL
Intervention: In-feed ZnO at 3000 mg/kg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control feed with 100 mg ZnO/kg
Number of subjects: 110
Study: 25046055

Group type: EXPERIMENTAL
Intervention: Mitiglinide 10 mg and voglibose 0.2 mg (three-times-daily before each meal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mitiglinide 10 mg and voglibose 0.2 mg (twice-daily before breakfast and dinner)
Number of subjects: 12

Group type: COMPARATOR
Intervention: DPP-4 inhibitor
Number of subjects: 12
Study: 22119455

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) at 2 × 2 (160/4.5 μg)
Number of subjects: 8424

Group type: COMPARATOR
Intervention: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) at 1 × 2 (160/4.5 μg)
Number of subjects: 8424
Study: 19885422

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide (bleached)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no bleaching)
Number of subjects: 60
Study: 17804386

Group type: EXPERIMENTAL
Intervention: Time-limited, trauma-focused group intervention
Number of subjects: 5

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 5
Study: 14716472

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, single oral dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11554699

Group type: EXPERIMENTAL
Intervention: Efficacy testing of cosmetic products
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10024837

Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat (2.5, 5, or 10 mg BID)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral quinapril (10, 20, or 40 mg OD)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral quinapril
Number of subjects: 55
Study: 7907012

Group type: EXPERIMENTAL
Intervention: Cold compressive Cryocuff dressing
Number of subjects: 76

Group type: COMPARATOR
Intervention: ACE wrap and ice pack (Control)
Number of subjects: 76
Study: 2240002

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study: 752875

Group type: EXPERIMENTAL
Intervention: Adjuvant BCG immunotherapy (intradermal and oral BCG)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no BCG immunotherapy)
Number of subjects: 107
Study: 31557064

Group type: COMPARATOR
Intervention: Fluorouracil plus radiotherapy
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus radiotherapy
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Number of subjects: 495
Study: 28494753

Group type: EXPERIMENTAL
Intervention: Problem-solving based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 25540929

Group type: EXPERIMENTAL
Intervention: Balloon occlusion hepatic venography
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wedged hepatic venography
Number of subjects: 58
Study: 24045604

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (BTX)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21774288

Group type: EXPERIMENTAL
Intervention: Fentanyl-propofol group (1 mcg/kg fentanyl)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline-propofol group (control group)
Number of subjects: 40
Study: 19628410

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2485
Study: 16728216

Group type: EXPERIMENTAL
Intervention: High blood glucose levels (quartile 4)
Number of subjects: 9020

Group type: COMPARATOR
Intervention: Low blood glucose levels (quartile 1)
Number of subjects: 9020

Group type: EXPERIMENTAL
Intervention: High blood glucose levels (quartile 4) after multivariable adjustment
Number of subjects: 9020

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide levels
Number of subjects: 9020

Group type: EXPERIMENTAL
Intervention: Troponin I levels
Number of subjects: 9020
Study: 15175887

Group type: COMPARATOR
Intervention: Closed reduction and immobilisation with a short‐arm cast for 4 weeks (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dorsal block splinting of the PIP joint with daily active exercise (Group B)
Number of subjects: 50
Study: 11775046

Group type: EXPERIMENTAL
Intervention: Venlafaxine (immediate release, N = 474; extended release, N = 377)
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs, N = 748)
Number of subjects: 2045

Group type: COMPARATOR
Intervention: Placebo (N = 446)
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 2045
Study: 9863097

Group type: EXPERIMENTAL
Intervention: Theo-polyphenols (TP) treatment
Number of subjects: 38
Study: 7934599

Group type: EXPERIMENTAL
Intervention: Topical bovine collagen applied weekly to the wound
Number of subjects: 111

Group type: COMPARATOR
Intervention: No collagen applied to the wound (control group)
Number of subjects: 111
Study: 3391871

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid
Number of subjects: 42

Group type: COMPARATOR
Intervention: Erythromycin stearate (ES) 500 mg tid
Number of subjects: 42
Study: 31915208

Group type: EXPERIMENTAL
Intervention: Combined use of contact aspiration (CA) and stent retriever (SR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stent retriever (SR) alone
Number of subjects: 0
Study: 31177243

Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 15

Group type: COMPARATOR
Intervention: Overground walking
Number of subjects: 15
Study: 27921320

Group type: EXPERIMENTAL
Intervention: Amiselimod 0.4 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Amiselimod 0.8 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 25195813

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT, DAT plus cilostazol)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT, aspirin and clopidogrel)
Number of subjects: 227
Study: 23449607

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg for 26 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 50
Study: 21814477

Group type: COMPARATOR
Intervention: Control (Group A): Intralipid(®) 2 ml as a placebo 15 min before the cervical plexus block and at the end of the surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Routine analgesia (Group B): Placebo 15 min before the cervical plexus block and flurbiprofen 50 mg at the end of the surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preemptive analgesia (Group C): Intravenous flurbiprofen 50 mg 15 min before the cervical plexus block and a placebo at the end of the surgery
Number of subjects: 90
Study: 18787838

Group type: EXPERIMENTAL
Intervention: Relevant object (green or red color)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irrelevant object (gray or white color)
Number of subjects: 0
Study: 17043939

Group type: COMPARATOR
Intervention: 10 mmHg CO(2) pneumoperitoneum (Group B)
Number of subjects: 109

Group type: COMPARATOR
Intervention: 10 mmHg CO(2) pneumoperitoneum + intraperitoneal normal saline infusion (Group C)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 14 mmHg CO(2) pneumoperitoneum (Group A)
Number of subjects: 109
Study: 15853118

Group type: EXPERIMENTAL
Intervention: DHA enriched foods (2 g fish oils)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Soya-protein (25 g)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 213
Study: 10640980

Group type: EXPERIMENTAL
Intervention: GM‐CSF (5 microg/kg subcutaneously)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9302547

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sober
Number of subjects: 60
Study: 8328892

Group type: EXPERIMENTAL
Intervention: Moderate resistance exercise program (12-week, 3 days per week, submaximal regimen using ankle and wrist weights and hand grip exerciser)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 27
Study: 3475553

Group type: EXPERIMENTAL
Intervention: Definitive diagnosis of food allergy and initiation of an appropriate elimination diet
Number of subjects: 132

Group type: COMPARATOR
Intervention: Double-blind placebo-controlled oral food challenges
Number of subjects: 132
Study: 30051441

Group type: EXPERIMENTAL
Intervention: Single-hand four-needle suture with sled-shaped needle three-tail fixed stitch
Number of subjects: 156

Group type: COMPARATOR
Intervention: Traditional tacking group
Number of subjects: 156
Study: 26883689

Group type: EXPERIMENTAL
Intervention: 600 IU vagitocin (oxytocin containing gel)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 68
Study: 24998009

Group type: EXPERIMENTAL
Intervention: Pump treatment
Number of subjects: 331

Group type: COMPARATOR
Intervention: Multiple daily injections
Number of subjects: 331
Study: 22904246

Group type: EXPERIMENTAL
Intervention: OMT (Osteopathic Manipulative Treatment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: LT (Light Touch)
Number of subjects: 21

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 21
Study: 20575278

Group type: EXPERIMENTAL
Intervention: Reduced traffic during the Olympic Games leading to lower O3 concentrations (approximately 30% lower)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: O3 concentrations during the Olympic Games
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meteorologic conditions during the Olympic Games
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention strategy of reduced traffic
Number of subjects: 0
Study: 18631000

Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thyroidectomy (MIVAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open thyroidectomy
Number of subjects: 0
Study: 15598943

Group type: EXPERIMENTAL
Intervention: Docetaxel-cisplatin (DC)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Vinorelbine-cisplatin (VC)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Docetaxel (A1)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Vinorelbine (B1)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Docetaxel (B2)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Vinorelbine (A2)
Number of subjects: 233
Study: 12601105

Group type: EXPERIMENTAL
Intervention: IFNbeta treatment (Avonex, Betaferon, Rebif-22)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Persistent NAb+ (neutralizing antibodies positive)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Isolated NAb+
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: NAb- (neutralizing antibodies negative)
Number of subjects: 191
Study: 10367554

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8909451

Group type: EXPERIMENTAL
Intervention: Dilute tropicamide eye drops
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 14
Study: 1854617

Group type: EXPERIMENTAL
Intervention: Higher serum concentration and area under the plasma concentration curve (AUC) of methotrexate (Mtx)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Methotrexate clearance
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Low 6‐mercaptopurine (6‐MP) doses due to neutropaenia and higher doses of Mtx
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Maintenance therapy in maximally tolerated doses
Number of subjects: 127
Study: 6147940

Group type: EXPERIMENTAL
Intervention: beta 1‐blockade (100 mg metoprolol)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: beta 1/2‐blockade (2 mg levobunolol)
Number of subjects: 16
Study: 30777651

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BoNT) prior to cognitive behavioral therapy (CBT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo prior to cognitive behavioral therapy (CBT)
Number of subjects: 14
Study: 29402767

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (20 mg once daily)
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185